Have synthetic antibodies been used for COVID 19?

Clinical trials have commenced evaluating if gimsilumab, an artificially synthesized antibody can reduce death risk among patients with Covid-19.  Covid-19 patients develop an excessive immune response causing acute respiratory distress syndrome (ARDS) and death. Gimsilumab is a monoclonal antibody that attacks the granulocyte macrophage-colony stimulating factor (GM-CSF), a key driver of lung hyper-inflammation.